ACIP February Meeting Cancelled: Report

Why It Matters

Without a convened ACIP, federal vaccine recommendations may stall, leaving states and providers to rely on divergent guidance, potentially fragmenting the national COVID‑19 response.

Key Takeaways

• ACIP meeting Feb 25‑27 2026 cancelled, no new date announced
• HHS leadership shake‑ups occur simultaneously with meeting cancellation
• Committee slated to debate COVID‑19 vaccine market status
• CDC’s shared‑decision guidance sparked internal ACIP disagreements
• States and pediatricians favor AAP guidance over CDC recommendations

Pulse Analysis

The ACIP, the CDC’s principal advisory body on immunization, traditionally meets twice a year to translate emerging data into national vaccine policy. Its February 2026 session, slated for February 25‑27, was abruptly cancelled with no reschedule announced, leaving a critical decision‑making window empty. The meeting was set to review the contentious COVID‑19 vaccine recommendations that have been under intense scrutiny since the CDC shifted to a shared‑decision model last October. The absence of a formal forum now delays any consensus on booster strategies or potential market withdrawals.

The cancellation coincides with a rapid turnover at the Department of Health and Human Services. Deputy Secretary Jim O’Neill and General Counsel Mike Stuart exited within days, and new senior counselors were installed by Secretary Xavier B. Kennedy. Observers note the timing suggests political recalibration of the vaccine advisory process, especially as ACIP members have publicly clashed over whether COVID‑19 products should remain available. The internal rift, highlighted by the vice‑chair’s accusations against FDA Commissioner Marty Makary, underscores a broader struggle between scientific guidance and administrative priorities.

With the federal advisory engine stalled, states and pediatric groups are already gravitating toward the American Academy of Pediatrics’ more traditional guidance, creating a patchwork of recommendations across the country. This fragmentation could complicate vaccine procurement, insurance coverage, and public confidence, especially if manufacturers interpret the uncertainty as a signal to adjust production. Stakeholders will be watching for any emergency convening of ACIP or alternative mechanisms, as a clear, unified stance remains essential for managing COVID‑19’s endemic phase and for preserving the credibility of U.S. public‑health institutions.